FEMASYS INC. 10-Q Summary: Period Ended June 30, 2025
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Femasys Inc. is a biomedical innovator focused on women's health, specifically infertility and permanent birth control. Key products include FemaSeed (intratubal insemination) and FemVue (diagnostic), which are FDA-cleared and commercialized globally. The company's primary U.S. product candidate, FemBloc (non-surgical permanent birth control), received CE mark certification in the European Union in June 2025 and is currently enrolling participants in a pivotal U.S. clinical trial.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Sales | $750,532 | $492,624 |
| Net Loss | $(10,482,761) | $(8,284,084) |
| Net Loss Per Share (Basic & Diluted) | $(0.39) | $(0.38) |
| Cash and Cash Equivalents (End of Period) | $3,218,067 | $13,525,898 |
| Convertible Notes Payable (Net) | $6,080,813 | $5,406,228 |
| Accumulated Deficit | $(137,681,018) | $(116,665,713) |
| Net Cash Used in Operating Activities | $(9,117,950) | $(8,894,780) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased by 52.4% ($257,908) year-over-year, driven by increased sales of FemaSeed and FemVue in both U.S. and international markets.
- Expense Increases: Total operating expenses rose 18.3% to $9.79 million. Research and Development (R&D) expenses increased 17.0% due to higher compensation and regulatory costs. Sales and marketing expenses surged 48.4% as the company expanded its commercial team.
- Other Expenses: "Other expense, net" increased significantly by 244.5% to $1.17 million, primarily due to non-cash amortization of debt discounts on convertible notes and expenses related to a new "Any Market Purchase Agreement."
- Inventory Build-up: Inventory increased by $2.19 million to $5.23 million, reflecting preparation for commercialization.
- Financing Activity: The company raised approximately $9.08 million in net cash from financing activities, including a June 2025 underwritten public offering and concurrent private placement, and sales under an "at-the-market" facility.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year from the issuance of the financial statements. Current cash reserves are projected to fund operations only into the early fourth quarter of 2025.
- Capital Needs: The company anticipates needing additional financing to fund the U.S. clinical development of FemBloc and ongoing commercialization efforts. Failure to secure funding could force delays or termination of operations.
- Nasdaq Compliance: The company received deficiency notices from Nasdaq regarding non-compliance with the Market Value of Listed Securities (MVLS) requirement (below $35 million) and the Minimum Bid Price requirement (below $1.00). The company has 180-day grace periods to regain compliance or face potential delisting.
- Convertible Notes: Senior unsecured convertible notes totaling $6.85 million principal mature in November 2025. The company must either convert these notes or pay them in cash, creating a significant near-term liquidity obligation.
- Regulatory Milestones: The company achieved full CE mark certification for the FemBloc system in the EU and announced its first commercial order in Spain. The U.S. pivotal trial is actively enrolling.
Investor Verification Checklist
- Verify the company's ability to raise additional capital before the November 2025 maturity of convertible notes.
- Monitor progress on Nasdaq compliance regarding MVLS and Minimum Bid Price to assess delisting risk.
- Review enrollment rates and interim data from the pivotal U.S. clinical trial for FemBloc.
- Assess the sustainability of the 52% revenue growth rate and the impact of the $2.2 million inventory increase on future cash flow.
- Confirm the terms and potential dilution impact of the new "Any Market Purchase Agreement" with Alumni Capital LP.